Cancer Research Annual Meeting 2010  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 6383, July 1, 2007. doi: 10.1158/0008-5472.CAN-06-4086
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Demo, S. D.
Right arrow Articles by Bennett, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Demo, S. D.
Right arrow Articles by Bennett, M. K.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Susan D. Demo, Christopher J. Kirk, Monette A. Aujay, Tonia J. Buchholz, Maya Dajee, Mark N. Ho, Jing Jiang, Guy J. Laidig, Evan R. Lewis, Francesco Parlati, Kevin D. Shenk, Mark S. Smyth, Congcong M. Sun, Marcy K. Vallone, Tina M. Woo, Christopher J. Molineaux and Mark K. Bennett

Proteolix, Inc., South San Francisco, California

Requests for reprints: Mark K. Bennett, Proteolix, Inc., South San Francisco, CA 94080. E-mail: mkbennett{at}proteolix.com.

Clinical studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma. However, significant toxicities have restricted the intensity of bortezomib dosing. Here we describe the antitumor activity of PR-171, a novel epoxyketone-based irreversible proteasome inhibitor that is currently in clinical development. In comparison to bortezomib, PR-171 exhibits equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome. In cell culture, PR-171 is more cytotoxic than bortezomib following brief treatments that mimic the in vivo pharmacokinetics of both molecules. Hematologic tumor cells exhibit the greatest sensitivity to brief exposure, whereas solid tumor cells and nontransformed cell types are less sensitive to such treatments. Cellular consequences of PR-171 treatment include the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis. Administration of PR-171 to animals results in the dose-dependent inhibition of the chymotrypsin-like proteasome activity in all tissues examined with the exception of the brain. PR-171 is well tolerated when administered for either 2 or 5 consecutive days at doses resulting in >80% proteasome inhibition in blood and most tissues. In human tumor xenograft models, PR-171 mediates an antitumor response that is both dose and schedule dependent. The antitumor efficacy of PR-171 delivered on 2 consecutive days is stronger than that of bortezomib administered on its clinical dosing schedule. These studies show the tolerability, efficacy, and dosing flexibility of PR-171 and provide validation for the clinical testing of PR-171 in the treatment of hematologic malignancies using dose-intensive schedules. [Cancer Res 2007;67(13):6383–91]




This article has been cited by other articles:


Home page
BloodHome page
F. Parlati, S. J. Lee, M. Aujay, E. Suzuki, K. Levitsky, J. B. Lorens, D. R. Micklem, P. Ruurs, C. Sylvain, Y. Lu, et al.
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Blood, October 15, 2009; 114(16): 3439 - 3447.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
B. Czesny, S. Goshu, J. L. Cook, and K. C. Williamson
The Proteasome Inhibitor Epoxomicin Has Potent Plasmodium falciparum Gametocytocidal Activity
Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4080 - 4085.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. A. Soucy, P. G. Smith, and M. Rolfe
Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer
Clin. Cancer Res., June 15, 2009; 15(12): 3912 - 3916.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. Lundgren, H. Zhang, J. Brekken, N. Huser, R. E. Powell, N. Timple, D. J. Busch, L. Neely, J. L. Sensintaffar, Y.-c. Yang, et al.
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
Mol. Cancer Ther., April 1, 2009; 8(4): 921 - 929.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
P. G. Richardson, C. Mitsiades, J. Laubach, D. Chauhan, T. Hideshima, and K. Anderson
Realizing the Anticancer Potential of Proteasome Inhibition: The Clinical Development of Bortezomib and Second-generation Proteasome Inhibitors
ASCO Educational Book, January 1, 2009; 2009(1): 163 - 170.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. G.M. Durie
Myeloma Therapy: 25 Years Forward--Immune Modulation Then and Now
J. Clin. Oncol., October 10, 2008; 26(29): 4698 - 4700.
[Full Text] [PDF]


Home page
BloodHome page
L. Paoluzzi, M. Gonen, G. Bhagat, R. R. Furman, J. R. Gardner, L. Scotto, V. D. Gueorguiev, M. L. Heaney, K. Manova, and O. A. O'Connor
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
Blood, October 1, 2008; 112(7): 2906 - 2916.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Oerlemans, N. E. Franke, Y. G. Assaraf, J. Cloos, I. van Zantwijk, C. R. Berkers, G. L. Scheffer, K. Debipersad, K. Vojtekova, C. Lemos, et al.
Molecular basis of bortezomib resistance: proteasome subunit {beta}5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Blood, September 15, 2008; 112(6): 2489 - 2499.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Paoluzzi, M. Gonen, J. R. Gardner, J. Mastrella, D. Yang, J. Holmlund, M. Sorensen, L. Leopold, K. Manova, G. Marcucci, et al.
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
Blood, June 1, 2008; 111(11): 5350 - 5358.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Z. Orlowski and D. J. Kuhn
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Clin. Cancer Res., March 15, 2008; 14(6): 1649 - 1657.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Chauhan, A. Singh, M. Brahmandam, K. Podar, T. Hideshima, P. Richardson, N. Munshi, M. A. Palladino, and K. C. Anderson
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma
Blood, February 1, 2008; 111(3): 1654 - 1664.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.